Updated:
NEXGEL
NEXGEL began in 2009 as a gel manufacturing operation before Levy repositioned the company around its hydrogel technology platform.
NEXGEL
NEXGEL began in 2009 as a gel manufacturing operation before Levy repositioned the company around its hydrogel technology platform. The firm went public via a direct listing on Nasdaq in 2021, raising capital to expand its contract manufacturing footprint and launch its own line of branded consumer products. The core intellectual property sits in a high-water-content, latex-free hydrogel that causes minimal skin trauma upon removal, which is critical for pediatric, geriatric, and cosmetic applications. The company's strategy splits between two revenue lines. On the contract manufacturing side, NEXGEL produces patches and masks for large consumer-health companies, with publicly confirmed relationships that have included Johnson & Johnson. On the branded side, it sells its own lines of hydrogel-based skincare and over-the-counter products, including the Silverseal wound-care line and the Medagel first-aid brand, directly through e-commerce channels and retail partnerships. The company also markets a line of recovery products under the NEXGEL Rx brand. Production spans two facilities — one in Langhorne, Pennsylvania, and a second Texas site — serving North American markets with plans for geographic expansion. NEXGEL operates with a lean internal team, publicly filing as an emerging growth company. The company has expanded its product pipeline through strategic acquisitions, including the 2022 purchase of a consumer-health brand portfolio to augment its direct-to-consumer reach. In July 2023, the firm appointed a Director of International Sales to target expansion outside the United States. The company's public equity is traded under the ticker NXGL, and its market capitalization has fluctuated with the volatile micro-cap healthcare sector. What differentiates NEXGEL from other small-cap medical-device companies is its dual identity as both a behind-the-scenes manufacturer for large strategics and an emergent consumer brand. This structure allows the company to generate predictable B2B revenue from its Toll-like manufacturing arm while building consumer brand equity on the same balance sheet, a setup that few firms at its scale attempt.
General information
Firm type
other
Year founded
2009
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Langhorne
Corporate office
Langhorne, PA, United States
Principals
Adam Levy
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs NEXGEL, and how is the company governed?
Adam Levy serves as Chief Executive Officer and leads the firm's executive team. NEXGEL operates as a public company listed on Nasdaq under the ticker NXGL, with a board of directors that includes independent members. Levy has overseen the company's transition from a private contract manufacturer into a publicly traded entity with both B2B and B2C product lines.
What is NEXGEL's core technology platform?
The company's core intellectual property is a high-water-content, latex-free hydrogel that adheres gently to skin and removes with minimal trauma. This polymer technology is the foundation for both the firm's contract manufacturing partnerships and its own branded consumer products. The hydrogels can be formulated to deliver active ingredients — including medicines, botanical extracts, or moisturizers — through the skin.
Does NEXGEL manufacture for other companies or only sell its own brands?
NEXGEL operates in both capacities. The company manufactures hydrogel patches and masks under contract for larger consumer-health and pharmaceutical companies, and has publicly disclosed Johnson & Johnson among its partners. Simultaneously, NEXGEL sells its own branded lines, including Silverseal wound-care products, Medagel first-aid gels, and the NEXGEL Rx recovery line.
Where does NEXGEL produce its hydrogel products?
The company runs two manufacturing facilities in the United States — its headquarters location in Langhorne, Pennsylvania, and a second production site in Texas. These plants serve the company's North American contract and branded business. As of mid-2023, the firm began building out an international sales function to extend its geographic reach.
What investment stages or sectors does NEXGEL target through acquisitions?
NEXGEL is not an investment firm — it is a publicly traded operating company that makes strategic acquisitions to expand its product portfolio and manufacturing capabilities. In 2022, the firm acquired a portfolio of consumer-health brands to accelerate its direct-to-consumer presence, demonstrating a preference for targets that can plug into its existing hydrogel platform or distribution channels.
Is NEXGEL a family office or an asset manager?
No. NEXGEL is a publicly traded, Nasdaq-listed medical-device and consumer-health company. It is not structured as a family office, investment fund, or asset management entity. The business generates revenue through manufacturing hydrogel products and selling branded consumer goods, rather than through capital allocation on behalf of a family or institution.
How does NEXGEL's manufacturing business compare to a toll-processing model?
The contract manufacturing side of NEXGEL's business bears structural similarities to a toll-processing operation: it produces hydrogel patches and masks to the specifications of its large corporate partners, generating fee-for-service revenue. The branded product side, however, operates as a traditional consumer-goods business with inventory risk and marketing expense, making the overall model a hybrid rather than a pure toll manufacturer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: